Tag: GlobeNewswire

VANCOUVER, British Columbia, Oct. 05, 2026 (GLOBE NEWSWIRE) — SHARC International Systems Inc. (CSE: SHRC) (FSE: IWIA) (OTCQB: INTWF) (“SHARC Energy” or the “Company”) is pleased to announce that its Board of Directors has approved grants of stock options and restricted share units (“RSUs”) pursuant to the Company’s equity incentive plans.

The Company has granted an aggregate of 9,590,000 stock options to certain directors, officers and eligible participants of the Company. Each option is exercisable at a price of $0.09 per common share, vests immediately and expires on October 2, 2029, subject to the terms of the Company’s Stock Option Plan and applicable grant documentation.

The Company has also granted an aggregate of 1,806,250 RSUs to non-executive employees pursuant to the Company’s Restricted Share Unit Plan. The RSUs will vest four months following the date of grant, subject to the terms of the RSU Plan and applicable award agreements.

The equity grants are intended to align the interests of the Company’s directors, management and employees with the long-term interests of shareholders and form part of the Company’s ongoing compensation and retention program.

About SHARC Energy  

SHARC International Systems Inc. is a world leader in energy recovery from the wastewater we send down the drain every day. SHARC Energy’s systems recycle thermal energy from wastewater, generating one of the most energy-efficient and economical systems for heating, cooling & hot water production for commercial, residential, and industrial buildings along with thermal energy networks, commonly referred to as “District Energy”.

SHARC Energy is publicly traded in Canada (CSE: SHRC), the United States (OTCQB: INTWF) and Germany (Frankfurt: IWIA) and you can find out more on our SEDAR profile.

Learn more about SHARC Energy: Website | Investor Page | LinkedIn | YouTube | PIRANHA | SHARC

ON BEHALF OF THE BOARD

Fred Andriano
Chairman

The Canadian Securities Exchange does not accept responsibility for the adequacy or accuracy of this release.

Forward-Looking Statements 

Certain statements contained in this news release may constitute forward-looking information. Forward-looking information is often, but not always, identified using words such as “anticipate”, “plan”, “estimate”, “expect”, “may”, “will”, “intend”, “should”, and similar expressions. Forward-looking information involves known and unknown risks, uncertainties and other factors that may cause actual results or events to differ materially from those anticipated in such forward-looking information. SHARC Energy’s actual results could differ materially from those anticipated in this forward-looking information because of regulatory decisions, competitive factors in the industries in which the Company operates, prevailing economic conditions, and other factors, many of which are beyond the control of the Company. SHARC Energy believes that the expectations reflected in the forward-looking information are reasonable, but no assurance can be given that these expectations will prove to be correct and such forward-looking information should not be unduly relied upon. Any forward-looking information contained in this news release represents the Company’s expectations as of the date hereof and is subject to change after such date. The Company disclaims any intention or obligation to update or revise any forward-looking information whether because of new information, future events or otherwise, except as required by applicable securities legislation. 

CONTACT: For investor inquiries, please contact:
Shane Dungey
Chief Executive Officer (SHARC Energy)
Telephone: 403.389.9911
Email: shane.dungey@sharcenergy.com

For media inquiries, please contact:
John Louis Fahie
Marketing Director
SHARC Energy
Telephone: 403.808.0882
Email: johnlouis.fahie@sharcenergy.com

Company Announcement No. 1173

This financial calendar lists the expected dates of publication of financial announcements and the Annual General Meeting in the 2027 financial year for DSV A/S:

2 February 2027	Annual Report 2026
18 March 2027	Annual General Meeting 2027. Any proposals for the agenda of the Annual General Meeting must be received no later than 3 February 2027.
21 April 2027	Interim Financial Report, First Quarter 2027
21 July 2027	Interim Financial Report, H1 2027
27 October 2027	Interim Financial Report, Third Quarter 2027

Contacts
Investor Relations
Stig Frederiksen, tel. +45 43 20 36 38, stig.frederiksen@dsv.com
Alexander Plenborg, tel. +45 43 20 33 73, alexander.plenborg@dsv.com

Yours sincerely,
DSV A/S

Attachment

• 1173 – Announcement (05.10.2026) – FINANCIAL CALENDAR 2027

• Combination broadens iRhythm’s cardiac monitoring portfolio, advances its multi-vitals strategy and expands iRhythm’s addressable market across the continuum of care.
• iRhythm’s commercial scale, health system relationships, market access expertise, and integrated clinical service capabilities are expected to accelerate VitalConnect’s growth and expand customer access.
• Transaction is expected to enhance iRhythm’s revenue growth rate beginning in 2027 while preserving iRhythm’s previously communicated 15% adjusted EBITDA margin target for 2027.

SAN FRANCISCO, Oct. 05, 2026 (GLOBE NEWSWIRE) — iRhythm Holdings, Inc. (Nasdaq: IRTC) today announced that it completed the previously announced acquisition of Vital Connect, Inc. (“VitalConnect”), a leader in wearable biosensor technology and ambulatory cardiac monitoring.

“Today marks an important milestone as iRhythm continues its evolution toward a broader cardiac monitoring and intelligence platform,” said Quentin Blackford, President and Chief Executive Officer of iRhythm. “VitalConnect brings complementary mobile cardiac telemetry (MCT), multi-vitals and monitoring capabilities to iRhythm’s established end-to-end cardiac monitoring service. Together, we can offer clinicians greater choice, serve more patients and customers across the continuum of care, and deepen customer relationships. We are pleased to welcome the VitalConnect team to iRhythm.”

“Joining iRhythm creates an opportunity to extend the reach and impact of VitalConnect’s technology,” said Peter Van Haur, Chief Executive Officer of VitalConnect. “By bringing together what our team has built with iRhythm’s scale, clinical expertise and customer reach, we believe we can accelerate the growth of our platform, expand access to our technology and create even greater value for clinicians and patients.”

VitalConnect’s cardiac monitoring platform supports multiple modalities, including complementary MCT capabilities. The VitalConnect platform offers differentiated features such as up to 30-day patient monitoring, four-in-one functionality, flexible service models and live look-in. VitalConnect’s platform also has the capability to monitor up to 11 physiological parameters, advancing iRhythm’s multi-vitals strategy beyond traditional ambulatory cardiac monitoring. Together with iRhythm’s end-to-end cardiac monitoring service, the combination creates a broader portfolio designed to serve distinct customer workflows as well as clinician and patient needs.

Strategic Fit and Financial Benefit

The acquisition immediately expands iRhythm’s capabilities across ambulatory cardiac monitoring, including MCT, creating a broader portfolio to serve diverse clinical needs. The combination also creates meaningful commercial acceleration opportunities by leveraging iRhythm’s scale, customer relationships and go-to-market capabilities.

Further, the addition of VitalConnect broadens iRhythm’s addressable market across the continuum of care, extending its reach into inpatient, remote and hospital-to-home settings. The transaction also brings together complementary technology, data and workflow capabilities that are expected to accelerate innovation and enhance customer solutions. Together, these benefits strengthen iRhythm’s long-term growth profile and position the company to serve more clinicians, customers and patients across a broader range of care settings.

As previously announced, the acquisition is expected to enhance iRhythm’s revenue growth rate, while preserving its previously communicated adjusted EBITDA margin target of 15% for 2027.

Transaction Detail

The purchase consideration consisted of $237.5 million in cash, subject to customary adjustments, funded from iRhythm’s balance sheet and up to 423,334 shares issued in connection with closing. In addition, iRhythm provided $10.0 million of working capital funding to VitalConnect between signing and closing.

iRhythm will provide updated 2026 financial guidance, inclusive of VitalConnect, during its third quarter earnings call on November 5^th, 2026.

About iRhythm Holdings, Inc.

iRhythm is a leading digital health care company with a mission to boldly innovate to create trusted solutions that detect, predict, and prevent disease. Combining its Zio® wearable biosensors and cloud-based data analytics with powerful proprietary algorithms, iRhythm distills data from millions of heartbeats into clinically actionable information. Through a relentless focus on patient care, iRhythm’s vision is to deliver better data, better insights, and better health for all. For more information, visit www.irhythmtech.com.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995. Forward-looking statements include, among other things, statements regarding the anticipated strategic, commercial, operational and financial benefits of the transaction; the ability to expand into new markets, care settings, customer categories and commercial partnerships; the potential to take advantage of and accelerate VitalConnect’s growth, deepen customer relationships and realize cross-selling opportunities; future product development, regulatory approvals and commercialization; the success of integration and the retention of key employees; the anticipated growth of the mobile cardiac telemetry category; and the expected impact on revenue growth, adjusted EBITDA and adjusted EBITDA margin. These statements may be identified by words such as “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “project,” “should,” “target,” “will” and similar expressions. Forward-looking statements are based on current assumptions and expectations and involve risks and uncertainties that could cause actual results to differ materially, including challenges in integrating VitalConnect and realizing anticipated benefits and synergies on the expected timeline or at all; business disruption or diversion of management’s attention; changes in market demand, reimbursement, competition or regulation; product development or regulatory delays; the loss of key VitalConnect employees, customers or partners; and unforeseen liabilities and future expenditures associated with the transaction; and the risks described under “Risk Factors” and elsewhere in iRhythm’s filings with the Securities and Exchange Commission, including its Quarterly Report on Form 10-Q filed on August 6, 2026. These forward-looking statements speak only as of the date of this press release. iRhythm undertakes no obligation to update them except as required by law.

Contacts

Investors	Media
Francis Pruell investors@irhythmtech.com	Kassandra Perry mediarelations@irhythmtech.com

Ghost Face, Billy the Puppet, Jason Voorhees, and Pinhead get a fashion-forward makeover this spooky season

SANTA MONICA, Calif., Oct. 05, 2026 (GLOBE NEWSWIRE) — JAKKS Pacific, Inc. (NASDAQ: JAKK), a leading global designer, manufacturer and marketer of toys and consumer products, is debuting Doll Haus of Dread™, a bold new collector fashion doll line that transforms horror’s most feared figures into high-style, display-worthy collectibles.

Launching exclusively at Walmart and Walmart.com in Fall 2026, this is horror fandom reimagined by one stitch, one slash, and one sinister silhouette at a time.

The debut lineup features dolls inspired by four of cinema’s most chilling icons: Ghost Face® as seen in the motion picture Scream, Billy the Puppet from Saw, Jason from Jason Universe franchise and Pinhead from Hellraiser. Each 11-inch fashion doll is crafted for collectors who want their shelves to scream style, featuring franchise-authentic fashions, signature accessories and nine points of articulation for striking poses as sharp and unforgettable as the characters themselves.

“With Doll Haus of Dread™, we’re reimagining some of horror’s most legendary figures as collectible works of art, blending authentic franchise storytelling with elevated fashion, sculptural detail, and artistic interpretation. Each doll is carefully crafted to honor the DNA of its respective property while introducing fresh creative perspectives that resonate with both horror enthusiasts and collectors. These aren’t simply dolls, they’re celebrations of the characters, films, and cultural impact that have defined the genre for decades. Doll Haus of Dread™ invites fans to experience horror icons in an entirely new way, where artistry, craftsmanship, and terror coexist beautifully,” said Dominick Lisi, Senior Vice President of Marketing at JAKKS Pacific.

JAKKS Pacific’s Doll Haus of Dread™ lives in the details–where elevated design meets cinematic dread through beautifully crafted dolls with meticulously styled accessories. Inspired by some of the films’ most iconic moments, our Jason Universe doll arrives in a slasher and summer camp-themed aesthetic complete with a signature hockey mask. While Pinhead commands the room in a Cenobite-inspired gown. Billy the Puppet steps out in a signature pinstripe tuxedo suit. Two Ghost Face dolls are available, one classic with the hooded silhouette that’s haunted screens for decades and a limited-edition version, available exclusively at Walmart.com, that wears a new bling encrusted mask.

Each doll retails for $39.97 and will hit shelves just in time for spooky season because nothing is more haunting than dolls dressed to kill.

Doll Haus of Dread™ marks the first chapter in a broader vision for Doll Haus as a unified collector destination. Beyond this debut collection, Doll Haus will expand into a house of sub-collections spanning fandom-driven properties, exclusive entertainment collections, and powerful collaborations, all designed to build a lifestyle destination for collectors rather than a single product line. As the platform grows, JAKKS plans to deepen the collector experience through direct-to-consumer exclusives, behind-the-scenes content, and a growing presence at conventions and events.

Visit dollhaushq.com for more information and follow @dollhaushq on Instagram and TikTok for the latest updates. Find Doll Haus of Dread™ at Walmart and Walmart.com this fall.

About JAKKS Pacific, Inc.:
JAKKS Pacific, Inc. is a leading designer, manufacturer and marketer of toys and consumer products sold throughout the world, with its headquarters in Santa Monica, California. JAKKS Pacific’s popular proprietary brands include Disguise®, Fly Wheels®, Charming™, Kidtopia™, Moose Mountain®, Maui®, ReDo® Skateboard Co., Sky Ball®, and Xtreme Power Dozer® as well as a wide range of entertainment-inspired products featuring premier licensed properties. Through their products and charitable donations, JAKKS is helping to make a positive impact on the lives of children. Visit us at www.jakks.com and follow us on Instagram (@jakkspacific.toys), X (@jakkstoys), YouTube (@JAKKSPacific), Facebook (@jakkspacific.toys) and LinkedIn (JAKKS Pacific).

Scream (2022) ⓒ 2026 Paramount Pictures. All Rights Reserved.

Ghost Face® Fun World Div., Easter Unlimited Inc. All Rights Reserved.

JASON UNIVERSE TM & Mask ⓒ Horror, Inc.

®, ™ & ⓒ 2026 Lions Gate Entertainment Inc. All Rights Reserved

‘Hellraiser™ Park Ave. Ent.
© 2026 Park Ave Ent. LLC & Clive Barker Ink, Inc.

Media Contact:
JAKKS Pacific
Jessica Kavanaugh
publicrelations@jakks.net

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/a622d77e-3197-43d1-9c95-e6141c1aee11

PHILADELPHIA, Oct. 05, 2026 (GLOBE NEWSWIRE) — Axalta Coating Systems (NYSE: AXTA), a leading global coatings company, will release its third quarter 2026 financial results at 6 a.m. ET on Thursday, October 29, 2026. The release and supporting materials will be posted to Axalta’s Investor Relations site.

In addition, the company will host a conference call at 8 a.m. ET on October 29, 2026. Chris Villavarayan, Chief Executive Officer and President, and Carl Anderson, Senior Vice President and Chief Financial Officer, will review the company’s financial performance for the period. A live webcast of the conference call will be available here. A replay of the webcast will be posted shortly after the call and will remain accessible through October 29, 2027.

The dial-in phone number for the conference call is 1-800-445-7795 and the conference ID is AXALTA. For those unable to participate, a replay of the call will be available through November 5, 2026. The replay dial-in number is 1-844-512-2921. The replay passcode is 11162641.

About Axalta
Axalta is a global leader in the coatings industry, providing customers with innovative, colorful, beautiful and sustainable coatings solutions. From light vehicles, commercial vehicles and refinish applications to electric motors, building facades and other industrial applications, our coatings are designed to prevent corrosion, increase productivity and enhance durability. With more than 150 years of experience in the coatings industry, the global team at Axalta continues to find ways to serve our more than 100,000 customers in over 140 countries better every day with the finest coatings, application systems and technology. For more information visit axalta.com and follow us on LinkedIn.

Axalta Coating Systems 1050 Constitution Ave. Philadelphia, PA 19112 axalta.com

Investor Relations Contact Colleen Lubic +1 610-999-9407 colleen.lubic@axalta.com

Media Contact media-relations@axalta.com

October 6–8 on Amazon.ca with Chromebooks from C$229, Windows laptops from C$329, and RTX 5060 gaming from C$1,999

KEY POINTS

• More time to save: ASUS offers run October 6–8 on Amazon.ca, covering Prime Big Deal Days on October 6–7
• Everyday value: Chromebooks from C$229 with up to 54% off, and Windows laptops from C$329
• Work and study upgrades: A 16GB Copilot+ PC at C$999, an ultralight OLED Zenbook A14 at C$1,199, and an OLED Vivobook 14 Flip at C$1,499
• Gaming and creator savings: Save C$600.99 on a 16-inch OLED Zenbook A16 or a 32GB OLED Vivobook S16, with RTX 5060 gaming from C$1,999

TORONTO, Oct. 05, 2026 (GLOBE NEWSWIRE) — ASUS today announced offers for Prime Big Deal Days on October 6–7, 2026, with savings of up to 54%. From Chromebooks under C$300 and Windows laptops from C$329 to OLED Copilot+ PCs, ROG and TUF gaming laptops, and ProArt creator systems, the lineup covers everyday essentials, gaming, and demanding creative work.

Everyday Laptops from C$229 with Up to 54% Off

ASUS Chromebook CX14 (CX1405CTAZ-AS01-CB)
MSRP: C$499 | Prime price: C$229 – Save C$270 (54% off) – Amazon.ca
14-inch Full HD display, Intel N50 processor, and 64GB of eMMC storage, running ChromeOS. At C$229 and 54% off, this is the lowest-priced model and biggest percentage saving in the featured lineup. Ideal for students and families who mainly use browser-based apps.

ASUS Chromebook CX15 (CX1505CKA-AS01-CB)
MSRP: C$599 | Prime price: C$299 – Save C$300 (50% off) – Amazon.ca
15.6-inch Full HD anti-glare display, Intel Celeron N4500 processor, 8GB of RAM, and 128GB of storage. Save C$300 on a larger ChromeOS screen with twice the storage of the featured CX14, still below C$300. Ideal for shared household use, schoolwork, and everyday browsing.

ASUS Vivobook Go 14 (L1404TA-AS01-CA)
MSRP: C$599.99 | Prime price: C$329 – Save C$270.99 (45% off) – Amazon.ca
14-inch Full HD display, Intel N150 processor, 4GB of RAM, and 128GB of UFS storage, with Windows 11 Home and one year of Microsoft 365 Personal included. Save C$270.99 on the lowest-priced Windows laptop in the featured lineup. Ideal for basic documents, email, and a first household laptop.

ASUS Vivobook Go 15 (E1504FA-AS52-CA)
MSRP: C$899 | Prime price: C$599 – Save C$300 (33% off) – Amazon.ca
15.6-inch Full HD display, AMD Ryzen 5 7520U processor, 8GB of RAM, and a 512GB SSD, with Windows 11 Home. C$300 off puts a larger screen, twice the memory, and more local storage than the featured Go 14 at C$599. Ideal for students and everyday users seeking an affordable Windows upgrade.

Work and Study Upgrades from C$999

ASUS Vivobook 14 (X1407QA-AS51-CA)
MSRP: C$1,499.99 | Prime price: C$999 – Save C$500.99 (33% off) – Amazon.ca
14-inch 1920 × 1200 display, Snapdragon X processor, 16GB of RAM, and a 512GB SSD. C$500.99 off brings this Copilot+ PC below C$1,000, with more memory and storage than the featured entry-level models. Ideal for students and hybrid workers seeking a compact everyday PC.

ASUS Zenbook A14 (UX3407QA-AS51-CA)
MSRP: C$1,599 | Prime price: C$1,199 – Save C$400 (25% off) – Amazon.ca
14-inch OLED display, Snapdragon X processor, 16GB of RAM, and a 1TB SSD, weighing under 1kg. This Copilot+ PC adds OLED and twice the storage of the featured Vivobook 14 for C$200 more. Ideal for commuters and students who carry their laptop every day, alongside a super-premium Ceraluminum^™ chassis in the lightest Zenbook ever.

ASUS Vivobook 14 Flip (TP3407AA-AS71T-CA)
MSRP: C$1,999 | Prime price: C$1,499 – Save C$500 (25% off) – Amazon.ca
14-inch OLED touchscreen, Intel Core Ultra 7 355 processor, 16GB of RAM, and a 512GB SSD. The 360-degree design switches between laptop and tablet modes, combining OLED and 2-in-1 flexibility at C$500 off. Ideal for students, teachers, and professionals who alternate between typing, presenting, touch-based work, and creative work.

ASUS Zenbook A16 (UX3607QA-AS51-CA)
MSRP: C$2,199.99 | Prime price: C$1,599 – Save C$600.99 (27% off) – Amazon.ca
16-inch 1920 × 1200 OLED display, Snapdragon X processor, 16GB of RAM, and a 1TB SSD. Save C$600.99 on a Copilot+ PC with a larger OLED workspace than the featured Zenbook A14 for C$400 more. Ideal for students and professionals who value more room for documents, multitasking, and media.

Gaming Deals from C$1,999 with Up to C$500 Off

ROG Strix G16 (G615JMR-AS73-CA)
MSRP: C$2,499 | Prime price: C$1,999 – Save C$500 (20% off) – Amazon.ca
16-inch 165Hz display, Intel Core i7-14650HX processor, NVIDIA GeForce RTX 5060 Laptop GPU, 16GB of RAM, and a 512GB SSD. C$500 off brings the ROG gaming lineup under C$2,000. Ideal for competitive players seeking a fast-refresh display and dedicated gaming hardware.

ASUS TUF Gaming A16 (FA608PM-AS94-CA)
MSRP: C$2,599 | Prime price: C$2,199 – Save C$400 (15% off) – Amazon.ca
16-inch Full HD+ display, AMD Ryzen 9 8940HX processor, NVIDIA GeForce RTX 5060 Laptop GPU, 16GB of RAM, and a 1TB SSD. C$400 off pairs a 16-core Ryzen 9 processor with twice the storage of the featured ROG Strix G16 for C$200 more. Ideal for gamers who multitask with streaming and creative apps.

OLED Tools for Creators with Up to C$600.99 Off

ASUS Vivobook S16 (S3607AA-AS72-CA)
MSRP: C$2,799.99 | Prime price: C$2,199 – Save C$600.99 (21% off) – Amazon.ca
16-inch 1920 × 1200 OLED display, Intel Core Ultra 7 355 processor, 32GB of RAM, and a 1TB SSD. Save C$600.99 on a larger OLED canvas with twice the memory of the featured 16GB models. Ideal for design students and professionals juggling creative apps and everyday work.

ASUS ProArt PZ14 (HT7407NA-AS91T-CA)
MSRP: C$2,899.99 | Prime price: C$2,499 – Save C$400.99 (14% off) – Amazon.ca
14-inch 3K OLED touchscreen, Snapdragon X2 Elite processor, and a 1TB SSD in a detachable design with a keyboard and stand cover. Save C$400.99 on a creator workspace that switches between laptop and tablet use. Ideal for photographers and creators who value touch input and flexible working positions.

AVAILABILITY

The highlighted ASUS offers run October 6–8, 2026 on Amazon.ca, covering Prime Big Deal Days on October 6–7, while supplies last. Check the relevant Amazon.ca listing for final pricing, eligibility, and offer terms.¹

Please contact your local ASUS representative for further information.

NOTES TO EDITORS

ASUS Amazon page: https://www.amazon.ca/stores/ASUS/page/789601BF-2483-42FA-995F-16B269FD8B1C
ASUS Deals (all year round): https://www.asus.com/ca-en/deals/
ASUS Homepage: https://www.asus.com/ca-en/
ASUS News Canada: https://www.asus.com/ca-en/news/
ASUS Ceraluminum: https://www.asus.com/ca-en/blog/what-is-ceraluminum/
ASUS AI PCs: https://www.asus.com/ca-en/content/asus-ai-pc/
ASUS Copilot+ PCs: https://www.asus.com/ca-en/content/copilot-plus-pc/
ASUS Pressroom: http://press.asus.com
ASUS Social Channels: Facebook | Instagram | YouTube | ASUS Global X

About ASUS

ASUS (2357.TW) is an innovative technology leader delivering the world’s most comprehensive AI solutions across Infrastructure, Physical AI, AI PC/Devices, and Engineering the AI Advantage. Guided by its “Ubiquitous AI. Incredible Possibilities.” strategy, ASUS is bringing enterprise-to-edge AI to life. The ASUS portfolio also includes the ROG and ProArt sub-brands, which serve gamers and creators worldwide.

¹ All prices are in Canadian dollars. Savings are calculated against MSRP, percentages are rounded to the nearest whole number. Offers are subject to change and availability. The included Microsoft 365 Personal subscription must be activated within six months of Windows activation.

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/c007d77c-2a80-4c24-a3e4-b27520973957

CONTACT: PRESS CONTACTS

Redoine Taoussi
Senior Public Relations Manager
Redoine_Taoussi@asus.com

License of up to 20 years and reciprocal share exchange would entitle RYET to a 10% royalty on qualifying technology receipts and 560,000 BGLC shares as Malaysia accelerates public healthcare digitalization

KUALA LUMPUR, Malaysia, Oct. 05, 2026 (GLOBE NEWSWIRE) — Ruanyun Edai Technology Inc. (NASDAQ: RYET) (“RYET” or the “Company”) today announced that it has signed a definitive agreement under which, on closing, RYET would grant BioNexus Gene Lab Corp. (NASDAQ: BGLC) (“BGLC”) an exclusive license of its Cogni AI document-intelligence platform for healthcare in Malaysia, together with a reciprocal share exchange. The agreement would take Cogni AI into a new industry and a new market outside China. RYET would be entitled to a 10% royalty on qualifying technology receipts collected by BGLC and its affiliates and would receive 560,000 BGLC shares at closing, 150,000 of them in exchange for 500,000 new RYET ordinary shares, giving it a direct stake in the partner that would take its technology to market.

The agreement comes as Malaysia accelerates the digitalization of its public healthcare system. In his National Day address on August 30, 2026, Prime Minister Anwar Ibrahim announced a RM1 billion allocation to accelerate healthcare digitalization involving 150 hospitals and 2,000 health clinics, and the Health Minister has said the additional funding will allow the Ministry of Health to expand and accelerate its electronic medical records system. In July, a deputy director of the ministry’s Digital Health Division said only about 10% of the public healthcare ecosystem had been brought online and that the ministry aims for a fully digital, patient-centered healthcare system within five to ten years. Neither RYET nor BGLC is a party to, or has been awarded any contract under, these government programs, and Cogni AI is not an electronic medical records system. The license would cover healthcare in Malaysia generally, and any public-sector business would depend on separate procurement.

The agreement would put RYET’s Formind Group strategy into practice. Formind Group, the identity under which RYET presents its group businesses, is built on taking AI developed in one industry into new industries and international markets. BGLC would lead local implementation and may build and brand its own applications on Cogni AI, while RYET would supply and support the platform. Formind Global Holdings Sdn. Bhd. (“Formind Global”), RYET’s wholly owned Malaysian subsidiary, would take part in the parties’ wider cooperation in Malaysia and Southeast Asia.

“Healthcare runs on records, and reading, checking and organizing records is what Cogni AI was designed to do,” said Maggie Fu, Chief Executive Officer of RYET. “Malaysia is investing to bring its health records online, and this agreement would give us a local partner with a shared stake in making Cogni AI work there. That is the Formind Group idea: take technology we have built and deployed in one industry and put it to work in the next, with partners who know the local market.”

From Highway Archives to Healthcare Records

In September, RYET announced the deployment of Cogni AI to digitize highway engineering archives in Ningxia, China, where it extracts catalog data, checks it against source documents and flags missing or out-of-sequence pages. Healthcare records demand the same accuracy, with stricter rules on data. Under the agreement, patient data must be hosted in Malaysia, the RYET Group may not access it from outside Malaysia, and clinical decisions remain with healthcare providers.

“Much of Malaysia’s public healthcare record-keeping is still paper-based,” said Sam Tan, Chief Executive Officer of BioNexus Gene Lab Corp. “Cogni AI, already deployed in China, would give us an engine for turning paper records into structured, checkable data, hosted in Malaysia under Malaysian rules. We plan to start in healthcare, and the agreement would let us take the platform into other industries in Malaysia as opportunities arise.”

Key Terms

• License: ten years from closing, renewable at BGLC’s option for two further five-year terms (up to 20 years in total), and exclusive in Malaysian healthcare for the full term, subject to the agreement’s milestone, cure and termination provisions. No rollout milestones have been agreed, and no fee is payable on renewal. While the license is exclusive, the RYET Group, including Formind Global, may pursue Cogni AI opportunities in the licensed fields in Malaysia only through BGLC or through RYET-led projects that BGLC approves.
• Other industries: BGLC may add any other industry in Malaysia, including education, by notice, with the same 10% royalty applying. Exclusivity in each added industry continues only if BGLC or an affiliate signs a customer contract in that industry within 12 months.
• Royalty: 10% of qualifying technology receipts that BGLC and its affiliates collect, net of specified deductions, with no minimum royalty or guaranteed revenue. Testing, clinical and consultation fees and separately identifiable services such as implementation and hosting are excluded.
• Support: RYET would provide deployment assistance, a 12-month warranty and, throughout the license term, security patches, fixes and general updates at no additional charge. If RYET stops supporting the technology for more than 60 days for any reason, including insolvency, it must deliver to BGLC the source code and related materials needed to maintain and support BGLC’s deployments, for use only for that purpose for the rest of the term.
• Shares: at closing, BGLC would issue 410,000 common shares to RYET for the license and a further 150,000 in exchange for 500,000 RYET ordinary shares, with no cash payment or true-up. The shares would be subject to transfer restrictions.
• License consideration: US$3.5 million, to be satisfied at closing by the 410,000 license shares. This is the contractual amount, not the shares’ market value or GAAP revenue. Based on Nasdaq closing prices on October 2, 2026, the last trading day before signing, of US$1.27 for BGLC and US$0.8599 for RYET, the 410,000 license shares had a quoted value of US$520,700; the 150,000 BGLC exchange shares, US$190,500; and the 500,000 RYET shares, US$429,950.
• Liability and governing law: each party’s liability is capped at US$1,000,000, except for fraud, willful misconduct and obligations to pay money. The cap does not apply to RYET’s obligation, if the RYET Group breaches the exclusivity or non-solicitation provisions, to pay BGLC the amounts received from the breaching activity, and BGLC may claim lost profits for RYET’s breach of the exclusivity, license-activation or Malaysia data-hosting provisions. From signing until closing, the RYET Group may not negotiate or grant rights to Cogni AI or a competing product in Malaysian healthcare to anyone else. The agreement is governed by Malaysian law, with disputes resolved by arbitration in Kuala Lumpur.

Under the agreement, the share exchange is separate from, and does not reduce, the license consideration. RYET’s accounting for the license and share issuances remains subject to final assessment, and any revenue would be recognized as performance obligations are satisfied. The transaction has not yet closed, and closing requires satisfaction of the applicable closing conditions and recording of the contemplated share issuances. Those conditions include BGLC’s written acceptance of the technology after testing, each party’s due diligence, required corporate and regulatory approvals, and any PRC approval, registration or license RYET needs to license and deliver the technology.

RYET is required to deliver the technology within 60 days after signing unless the parties agree another date in writing. Either party not in default may terminate if closing has not occurred by March 31, 2027, unless the parties extend that date in writing. Either party may terminate for the other’s uncured material breach or insolvency. BGLC may also terminate if the technology fails acceptance testing a second time, or within 90 days after learning of a change of control of RYET or of the Cogni AI business. Where BGLC could terminate for RYET’s breach, insolvency or change of control, it may instead keep the license, including exclusivity, in force for the rest of the term.

About Ruanyun Edai Technology Inc.

Ruanyun Edai Technology Inc. is an AI-driven education technology company focused on intelligent content recognition, automated assessment and next-generation learning systems. The Company has historically developed and provided AI-enabled teaching, learning and assessment solutions, including smart homework, smart examination and digital education services, and since September 2025 has provided campus operations and student-life services through its Smart Campus Services business. The Company is presenting its group businesses under the Formind Group identity as part of its broader strategy to expand AI education, language learning, institutional education support and global technology initiatives. Additional information about Formind Group is available at www.formind.group. Information on that website is not part of this press release.

About BioNexus Gene Lab Corp.

BioNexus Gene Lab Corp. (NASDAQ: BGLC) is a technology-focused company advancing innovation across biotechnology, precision diagnostics, and emerging healthcare platforms. Through strategic investments, partnerships, and licensing arrangements, BGLC supports the development and commercialization of next-generation healthcare technologies. BGLC is building a platform spanning precision medicine, gene-based technologies, AI-integrated healthcare solutions, and selected biotechnology infrastructure opportunities in Asia and the United States. Through its subsidiaries and strategic initiatives, BioNexus is focused on expanding access to advanced molecular diagnostics, supporting regional commercialization of innovative healthcare technologies, and developing cross-border platforms for biotechnology growth.

The securities to be issued under the agreement have not been and will not be registered under the U.S. Securities Act of 1933 and may not be offered or sold in the United States absent registration or an applicable exemption from registration. This press release does not constitute an offer to sell or a solicitation of an offer to buy any securities.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995, including statements in the quotations from the management of both companies. These include statements about completion of the transaction, the expected benefits of the license and share exchange, the commercialization of Cogni AI in Malaysia, healthcare digitalization in Malaysia, the Formind Group strategy, future royalties and accounting treatment. Words such as “would,” “may,” “expect,” “plan,” “intend,” “aim” and similar expressions identify forward-looking statements.

These statements are based on current expectations and involve risks and uncertainties that could cause actual results to differ materially, including: whether the closing conditions are satisfied, including BGLC’s acceptance testing and each party’s due diligence; whether the licensed technology, which was developed in China and includes character-recognition functions, requires a PRC export license under China’s Catalogue of Technologies Prohibited or Restricted from Export, which RYET has not obtained and which could be delayed or refused, and the ownership of the technology within the RYET Group; the financial condition of each party, each of which has disclosed substantial doubt about its ability to continue as a going concern; BGLC’s limited current revenue, the volatility of its share price and the potential impairment of RYET’s investment; dilution from share issuances by either party; customer demand and adoption, including public-sector procurement decisions, and the performance of Cogni AI on English- and Malay-language records; data-protection, healthcare and cross-border technology regulation; and accounting judgments and revenue recognition. The agreement does not assure completion, future customer contracts, revenue or profitability.

Forward-looking statements speak only as of the date of this press release. Additional risks are described in RYET’s reports filed with or furnished to the U.S. Securities and Exchange Commission, including its most recent Annual Report on Form 20-F, and in BGLC’s reports filed with the SEC. Readers should not place undue reliance on these statements, and neither RYET nor BGLC undertakes any obligation to update them except as required by law.

Investor Relations and Corporate Communications

FSR Capital, a FSR Group Company
Email: ir@fsr.group

FSR Capital, which provides investor relations services to RYET, is part of FSR Group, which is owned by Sam Tan (Su-Leng Tan Lee), Chief Executive Officer, President, a director and a shareholder of BGLC. FSR provides only investor relations services to RYET under an ongoing engagement and receives no fee or other compensation in connection with the transaction. Neither Mr. Tan nor FSR holds RYET shares.

-24-Month Crossover Analysis: Patients Starting Deramiocel After a Year on Placebo Slowed Upper Limb Decline by 76% Compared with Their Own Prior Year-

-At 24 Months, Both Groups Showed Slower Decline in Upper Limb Function Than Natural History Predicts-

-Data Included in Deramiocel BLA Major Amendment; PDUFA Target Action Date November 22, 2026-

-Webinar Scheduled for October 7, 2026, at 1:00 p.m. ET in Collaboration with PPMD to Discuss the Data-

SAN DIEGO, Oct. 05, 2026 (GLOBE NEWSWIRE) — Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment of rare diseases, today announced positive new data from its ongoing HOPE-3 open-label extension (OLE) study for its lead asset, Deramiocel, for the treatment of upper limb impairment in Duchenne muscular dystrophy (DMD). The data were highlighted in a late-breaking poster presentation at the 31^st Annual Congress of the World Muscle Society (WMS) in Hiroshima, Japan, supporting HOPE-3’s previously reported 12-month results, which were also presented in a separate oral session on Deramiocel’s musculoskeletal and cardiac efficacy.

Key results from the late-breaking abstract are summarized below.

HOPE-3 Open-Label Extension: Upper Limb Function (PUL 2.0)

PUL 2.0 Total Score	Year 1 LS mean changea	Year 2 (OLE) LS mean changea	Difference, Year 2 vs Year 1 (95% CI)	Reduction in rate of declinec
Year-by-year change
Placebo arm (delayed start)b	−2.05 on placebo n=52	−0.49 on Deramiocel n=49	1.56 (0.47 to 2.64)	76%
Deramiocel arm (early start)b	−0.95 on Deramiocel n=54	−0.89 on Deramiocel n=49	0.05 (−1.03 to 1.14)	—
Month 24 change vs natural historyd
	Observed at Month 24e		Predicted by natural history
Placebo arm 12 months on Deramiocel	−3.76		−5.35
Deramiocel arm 24 months on Deramiocel	−3.42		−5.88

ITT population: 106 randomized; 98 entered the OLE (49 per arm). Negative values indicate decline. 95% CIs are two-sided. No alpha was allocated to these open-label analyses, and the extension was not powered for Month 24 comparisons.
^aLeast-squares mean change from a mixed model for repeated measures, with each year measured from its own starting point (Day 0 or Month 12) and adjusted for starting score, cohort, site and slow-progressor status.
^bGroups are named by original randomized assignment.
^cDifference as a percentage of the Year 1 decline on placebo.
^dObserved mean change (unadjusted) vs a natural history model (Michaëls 2025; Niks 2026) that predicts each patient’s decline from baseline score, age and ambulatory status. In its untreated year, the Placebo arm tracked the model (−2.7 observed vs −2.9 predicted at Month 12) and a published non-ambulant cohort (about −2.7 points per year; Coratti 2025). Descriptive only; no matching or statistical testing.
^ePatients assessed at Month 24: n=42 (Placebo arm), n=40 (Deramiocel arm).

“Upper limb function is critical to quality of life for young men with DMD because it is directly tied to their independence,” said Craig McDonald, MD, Principal Investigator of the HOPE-3 trial at UC Davis Health. “When the young men who had been declining on placebo started Deramiocel, their rate of upper limb loss dropped by roughly 75% in their first year of treatment. Just as important, patients who were on Deramiocel both years declined at a similar rate in year 1 and year 2, which suggests that the slower decline was triggered by starting treatment, not the passage of time. Being able to follow the same young man before and after he starts treatment is a powerful way to see a treatment effect, and what we saw was consistent with the randomized, placebo-controlled period. As a clinician seeing these patients, I have had very little to offer them that could meaningfully slow the progression of upper limb functional loss once they were non-ambulant. These data suggest there could be a way to treat this aspect of the disease. Their arms are how they feed themselves, control their wheelchairs and use their phones, and how they stay independent. Time is muscle, and slowing that loss means more time doing the things that matter most to them.”

“These results add to a growing body of evidence for Deramiocel,” said Linda Marbán, Ph.D., CEO of Capricor. “What we saw in the HOPE-3 open-label extension aligns with our previous clinical studies, which together show the same pattern across multiple years of treatment. The FDA has received these data as part of the recent major amendment to the Deramiocel Biologics License Application, along with extensive sensitivity and robustness analyses we produced to support the results of the HOPE-3 randomized clinical trial. We will continue to work with the FDA through the remainder of the review, ahead of the November 22, 2026, PDUFA target action date.”

Copies of all Capricor WMS presentations will be made available in the publications section of the Capricor website. The full WMS program is available at wms2026.com/page/programme.

Webinar Information

A webinar is scheduled for Wednesday, October 7, 2026, at 1:00 p.m. ET in collaboration with Parent Project Muscular Dystrophy (PPMD) to discuss these results in more detail. To register for the webinar, please click here. For additional details, please visit Parent Project Muscular Dystrophy’s website.

About the HOPE-3 Study

HOPE-3 is a Phase 3, randomized, double-blind, placebo-controlled trial evaluating Deramiocel in patients with Duchenne muscular dystrophy. The study enrolled 106 patients, randomized to receive Deramiocel or placebo administered intravenously every three months over a 12-month treatment period. One-year results were published in The Lancet in July 2026. Patients who completed the randomized portion of the study were eligible to continue receiving Deramiocel in an open-label extension (OLE).

About Duchenne Muscular Dystrophy

Duchenne muscular dystrophy (DMD) is a severe, X-linked genetic disorder characterized by progressive muscle degeneration affecting the skeletal, respiratory, and cardiac muscles. It is caused by the absence of functional dystrophin, a key structural protein in muscle cells. DMD affects approximately 15,000 individuals in the United States and primarily impacts boys. Over time, deterioration of the heart muscle leads to cardiomyopathy and heart failure, the leading cause of death in DMD. There is no cure, and treatment options remain limited.

About Deramiocel

Deramiocel (CAP-1002) consists of allogeneic cardiosphere-derived cells (CDCs), a rare population of cardiac cells that have been shown in preclinical and clinical studies to exert immunomodulatory and anti-fibrotic actions in the preservation of skeletal and cardiac muscle function in muscular dystrophies such as DMD. CDCs act by secreting extracellular vesicles known as exosomes, which target macrophages and alter their expression profile to adopt a healing rather than pro-inflammatory phenotype. For the treatment of DMD, Deramiocel holds Orphan Drug, RMAT and Rare Pediatric Disease designations in the U.S., and Orphan Drug and ATMP designations in Europe. The Rare Pediatric Disease designation may qualify Capricor for a Priority Review Voucher upon approval.

About Capricor Therapeutics

Capricor Therapeutics (NASDAQ: CAPR) is a biotechnology company dedicated to advancing cell and exosome-based therapeutics for the treatment of rare diseases. Our lead product candidate, Deramiocel, is an allogeneic cardiac-derived cell therapy in late-stage development for the treatment of Duchenne muscular dystrophy (DMD), evaluated in clinical studies for its potential to preserve skeletal and cardiac muscle function. Capricor is also advancing its proprietary StealthX™ exosome platform for the targeted delivery of oligonucleotides, proteins, and small-molecule therapeutics across a range of diseases. At Capricor, we are committed to delivering new therapies for patients with rare diseases. For more information, visit capricor.com and follow Capricor on Facebook, Instagram and X.

Cautionary Note Regarding Forward-Looking Statements

Statements in this press release regarding the efficacy, safety, and intended utilization of Capricor’s product candidates; the initiation, conduct, size, timing and results of clinical trials; the pace of enrollment of clinical trials; plans regarding regulatory filings, future research and clinical trials; regulatory developments involving products, including future interactions with regulatory authorities and the ability to obtain regulatory approvals or otherwise bring products to market; manufacturing capabilities; dates for regulatory meetings; the potential that required regulatory inspections may be delayed or not be successful which would delay or prevent product approval, revenue and reimbursement estimates, projected terms of definitive agreements, our financial position, our possible uses of existing cash and investment resources; results of securities litigation; and statements regarding our litigation with Nippon Shinyaku Co., Ltd. and NS Pharma, Inc., including the nature of the dispute, our expectations regarding any legal proceedings, and our ability to commercialize Deramiocel independent of our existing distribution agreement and any other statements about Capricor’s management team’s future expectations, beliefs, goals, plans or prospects constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements that are not statements of historical fact (including statements containing the words “believes,” “plans,” “could,” “anticipates,” “expects,” “estimates,” “should,” “target,” “will,” “would” and similar expressions) should also be considered to be forward-looking statements. There are a number of important factors that could cause actual results or events to differ materially from those indicated by such forward-looking statements. More information about these and other risks that may impact Capricor’s business is set forth in Capricor’s Annual Report on Form 10-K for the year ended December 31, 2025, as filed with the Securities and Exchange Commission on March 17, 2026 and in our Quarterly Report on Form 10-Q for the quarter ended June 30, 2026, as filed with the Securities and Exchange Commission on August 14, 2026. All forward-looking statements in this press release are based on information available to Capricor as of the date hereof, and Capricor assumes no obligation to update these forward-looking statements.

Deramiocel and Capricor’s StealthX™ exosome therapeutics are investigational and have not been approved for commercial use in any indication.

For more information, please contact:

Capricor Media Contact:
Caitlin Kasunich / Raquel Cona
KCSA Strategic Communications
ckasunich@kcsa.com / rcona@kcsa.com
212.896.1241 / 516.779.2630

Capricor Company Contact:
AJ Bergmann, Chief Financial Officer
abergmann@capricor.com
858.727.1755

Agreement brings together RAYEL’s scientific foundation, KRTL’s U.S. commercialization strategy and expanding regulatory, API and research capabilities

Lakewood, CO, Oct. 05, 2026 (GLOBE NEWSWIRE) — KRTL Holding Group Inc. (OTC: KRTL) (“KRTL” or the “Company”) today announced that its wholly owned subsidiaries, KRTL International Corp. and KRTL Biotech Inc., have executed a definitive strategic partnership agreement with CENTRO DE INVESTIGACIONES QUIMICAS, S.R.L. (“CIQ”) for the continued development and commercialization of the RAYEL platform.

The agreement marks an important transition for RAYEL. What began under a Memorandum of Understanding now moves into a binding framework designed to support U.S. commercialization, manufacturing evaluation, strategic partnerships, regulatory coordination, capital development and additional potential applications for the platform.

For KRTL, the timing is significant. The Company has been building the pieces around RAYEL – strengthening its U.S. regulatory and pharmaceutical/API capabilities, organizing the platform’s technical and commercial record, developing potential partner pathways and opening discussions with universities regarding potential research collaboration.

KRTL Holding Group management stated: “This agreement brings together work that has been developing on several fronts. We have CIQ’s scientific and technical foundation, a defined U.S. commercialization strategy, growing regulatory and API expertise through KRTL Biotech, and active discussions with universities. We can now begin bringing those pieces together around RAYEL and evaluating where the platform has the strongest opportunity to advance.”

The Platform and the Path

Under the agreement, KRTL will lead the U.S. commercialization pathway for RAYEL, while CIQ continues its scientific and technical role. The parties will coordinate strategy and make material project decisions together.

KRTL and CIQ are evaluating multiple potential uses and commercial pathways for RAYEL.

The platform has a documented beverage-facing TTB pathway for its documented product scope, while the parties are also evaluating how RAYEL could be developed across additional pharmaceutical/API-oriented and other potential applications.

Rather than building RAYEL around a single prospective market, KRTL intends to evaluate where the platform, its scientific record and future research may have the strongest commercial fit.

The Opportunity Around RAYEL

That strategy is taking shape against a growing global market for plant-derived extracts.

MarketsandMarkets estimates the global plant extracts market at approximately $47.54 billion in 2025 and projects it to reach $85.28 billion by 2030, representing a 12.4% compound annual growth rate. The market spans applications including food and beverages, pharmaceuticals, dietary supplements and cosmetics. Source: MarketsandMarkets

KRTL has been working to build the capabilities needed to evaluate RAYEL within that broader environment.

Through KRTL Biotech, the Company engaged Justin Abril as President-Designate and Strategic Regulatory & API Consultant, adding experience in regulatory strategy, pharmaceutical/API development planning, API/CMC documentation, controlled-substance compliance planning, import/export pathway review and partner diligence.

KRTL is also in active discussions with universities regarding potential research collaboration related to RAYEL, creating another potential avenue for scientific and technical development around the platform.

Put together, the strategy is becoming clearer: CIQ provides the scientific and technical foundation; KRTL is building the commercial, regulatory, research and partner-development infrastructure around it; and the definitive agreement provides the framework for those efforts to move forward together.

What Comes Next

The focus now turns to translating that framework into qualified opportunities.

KRTL and CIQ will continue developing the RAYEL technical and commercial record while evaluating research, manufacturing, strategic and commercial relationships in the United States. As individual opportunities mature, they can move into project-specific agreements appropriate to the particular pathway.

KRTL management added: “Signing the agreement is a milestone, but what matters now is what we build from it. Our focus is getting RAYEL in front of the right researchers, technical groups, manufacturers and commercial partners and allowing the science, the documentation and the market opportunity to guide where we go next.”

Any regulated manufacturing, controlled-substance handling, testing, importation, formulation, pharmaceutical/API development or distribution would be performed through appropriately qualified and authorized external parties.

About KRTL Holding Group Inc.

KRTL Holding Group Inc. (OTC: KRTL) operates through specialized subsidiaries focused on life sciences, international project development, healthcare and related emerging commercial opportunities.

KRTL Biotech Inc. supports life-sciences platform development, regulatory and pharmaceutical strategy, partner coordination and commercialization. KRTL International Corp. serves as the Group’s international, federal-facing and cross-border project-development and partnering platform.

KRTL Holding Group: www.krtlholding.com
KRTL International: www.krtl-icc.com
Contact: info@krtlholding.com

Forward-Looking Statements

This press release contains forward-looking statements regarding RAYEL development, potential university and research collaborations, commercialization, manufacturing evaluation, pharmaceutical/API-oriented and other potential applications, strategic partnerships, regulatory pathways, financing and future commercial opportunities. Such statements involve risks and uncertainties, and actual results may differ materially from those expressed or implied.

RAYEL remains subject to technical validation, documentation, partner and institutional diligence, financing considerations, applicable regulatory requirements and future agreements. Evaluation of pharmaceutical/API-oriented, alkaloid-related, whole-extract or other regulated pathways does not mean that RAYEL has been approved or authorized for those uses. Any regulated activities would require the applicable licenses, registrations, approvals and appropriately qualified external parties.

The plant-extract market figures referenced above are third-party industry estimates from MarketsandMarkets and describe the broader global plant-extract industry. They are not estimates of RAYEL’s addressable market, future revenues, valuation or expected market share.

Discussions with universities and other prospective research, manufacturing, strategic or commercial partners remain subject to further diligence and definitive agreements where applicable. The execution of the CIQ agreement does not represent FDA approval, DEA authorization, secured financing or commercial launch.

CONTACT: www.krtlholding.com
info@krtlholding.com

Contact: 855-KRTL-HLD

www.krtlbiotech.com
info@krtlbiotech.com

www.krtl-icc.com
info@krtl-icc.com

VANCOUVER, British Columbia, Oct. 05, 2026 (GLOBE NEWSWIRE) — AnorTech Inc. (“AnorTech” or the “Company”) (TSX Venture Exchange “ANOR”; OTCQB “ANORF”) is pleased to announce that Greenland Mines Ltd. (“Greenland Mines”) (Nasdaq: GRML) has exercised in full its option under the share exchange agreement between the two companies (the “Agreement”) (see NR2026-04) to acquire an additional 25,168,669 common shares of AnorTech (the “AnorTech Shares”) at a deemed price of C$0.30 per share (the “Transaction”). On closing of the Transaction (“Closing”), Greenland Mines’ ownership will double from approximately 9.9% to approximately 19.9% of AnorTech’s issued and outstanding common shares, establishing Greenland Mines as a major strategic shareholder.

In exchange for the AnorTech Shares, Greenland Mines will issue common shares with a deemed value of approximately US$5,298,000 (C$7,550,600) of its common shares (the “Greenland Mines Shares”) to AnorTech giving AnorTech a meaningful position in a Nasdaq-listed company and increased access to US markets. The exact number of the Greenland Mines Shares will be based on the 10-day volume-weighted average trading price ending immediately before Closing of Greenland Mines’ common shares on Nasdaq at the time of closing.

Jim Cambon, President of AnorTech, commented:

“Greenland Mines’ decision to exercise its option in full is a strong endorsement of what we are building at AnorTech. Greenland Mines understands the value we are creating from Greenland anorthosite and its exciting future as a key component in the aluminum critical mineral supply chain and as the primary material for lunar project development. We are moving our smelter grade alumina and high purity aluminum technologies towards commercialization while continuing to advance our anorthosite lunar applications with successful test programs on both 3D-printable and refractory cements. We are working with a number of groups in the space industry who are using our anorthosite as a lunar simulant and we expect this sector to grow as lunar programs ramp up. We look forward to maximizing the synergies between our companies and working with Greenland Mines as a strategic shareholder as we advance our lunar materials, smelter grade alumina and high purity alumina programs.”

Bo Møller Stensgaard, President of Greenland Mines, commented:

“In June we said this investment was about moving into the midstream of the critical-materials value chain. Since then, it has become clear that AnorTech’s anorthosite is also relevant to a value chain that is about to grow significantly — the industrial supply chain of the Moon. The lunar highlands, where future space missions are planned to land, are comprised largely of anorthosite. Every landing pad, habitat wall, radiation shield and tonne of aluminum that will one day be produced from lunar regolith starts with the same rock AnorTech is developing at Gronne Bjerg.

Doubling our position gives Greenland Mines shareholders exposure to zero-waste smelter grade alumina and high purity alumina on Earth and to the materials science of building the Moon with the Moon itself. Aluminum is designated as a critical metal in the United States and Canada and AnorTech’s alumina could support both the aluminum smelters in the United States and semiconductor manufacturers who require high purity alumina. Greenland’s strategic importance to the United States and its allies was underscored by the security agreement signed by the United States, Denmark and Greenland on September 22, 2026; we believe AnorTech’s anorthosite is strategically important a great deal further from home too.”

Transaction Terms

The option to increase Greenland Mines’ ownership of AnorTech to 19.9% was granted under the share exchange agreement between Greenland Mines and AnorTech dated June 15, 2026 and announced on June 16, 2026. Under that agreement, Greenland Mines acquired its initial 19,958,503 AnorTech shares, and AnorTech announced completion of that transaction on June 30, 2026. On Closing, Greenland Mines will hold 45,127,172 AnorTech shares representing approximately 19.9% of AnorTech’s issued and outstanding share capital. The AnorTech Shares will be subject to a contractual lock-up period of 60 months from the date of issuance.

The Greenland Mines Shares issued to AnorTech will be subject to a contractual lock-up period as to one-half of the Greenland Mines Shares for 12 months from Closing and a contractual lock-up period as to the remaining one-half of the Greenland Mines Shares for 24 months from Closing. AnorTech currently owns 318,000 shares of Greenland Mines from previous transactions (see NR2026-04 and NR2026-06).

Closing is subject to customary closing conditions, including acceptance by the TSX Venture Exchange (the “TSXV”). No finder’s fee is being paid in connection with the Transaction.

About Greenland Mines

Greenland Mines Ltd. is a Nasdaq-listed resource development and mining company focused on the development of the Skaergaard Project in southeast Greenland and the Sarfartoq neodymium-praseodymium rare earths project in southwest Greenland. Greenland Mines’ strategy is centered on building a multi-asset platform with exposure to rare earth magnet materials, precious metals and select midstream processing opportunities, while advancing its assets and broader North Atlantic Critical Metals Corridor vision linking Greenland resources with allied downstream jurisdictions and industrial infrastructure. Greenland Mines has working capital of approximately C$100 million.

About AnorTech Inc.

AnorTech is pioneering the next generation of sustainable materials from anorthosite with over 12 years experience in developing anorthosite products and 25 years experience exploring, building and operating projects in Greenland. The Company owns 100% of the Gronne Bjerg anorthosite project in Greenland which is strategically located just 80km northeast of Nuuk, the capital of Greenland, on open tidewater, a deep-water port location and adjacent to significant hydroelectric potential.

AnorTech is advancing multiple product lines towards commercialization, including:

• Zero-waste Smelter Grade Alumina (SGA) and High Purity Alumina (HPA)
• Next generation alumina-based catalysts for CO2 capture
• CO2-free refractory cement and advanced 3D-printable cement
• Lunar construction materials using anorthosite-based concrete

The Company filed a U.S. provisional patent in 2025 to protect its proprietary sustainable SGA and HPA process (see NR2025-01) and shipped 15 tonnes of Gronne Bjerg anorthosite to Ontario in preparation for pilot plant testing. AnorTech is actively pursuing strategic industry partnerships to accelerate commercialization. AnorTech has over C$3 million in working capital.

ON BEHALF OF THE BOARD OF DIRECTORS

“Jim Cambon”

President and Director

For further information:
Ph: 778-373-2164
www.anortechinc.com

Neither the TSXV nor its Regulation Services Provider (as that term is defined in the policies of the TSXV) accepts responsibility for the adequacy or accuracy of this release.

CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING INFORMATION: This news release contains statements that, to the extent they are not recitations of historical fact, may constitute “forward-looking statements” within the meaning of applicable Canadian securities laws. The Company uses words such as “may”, “would”, “could”, “will”, “likely”, “expect”, “believe”, “intend” and similar expressions to identify forward-looking statements. Forward-looking statements in this news release include, but are not limited to, statements regarding: the completion of the Transaction and receipt of necessary regulatory approvals, including TSXV approval; the issuance of the AnorTech Shares and the Greenland Mines Shares; expected benefits of the strategic relationship between AnorTech and Greenland Mines; and Greenland Mines’ development of its multi-asset platform and the North Atlantic Critical Metals Corridor. Such forward-looking statements are based on a number of assumptions of management, including, without limitation: that the Transaction will complete as currently planned on the anticipated timeline; that the Company will be able to obtain any necessary third party and regulatory approvals required for the Transaction, including TSXV approval; that each Mines will satisfy the remaining conditions to Closing; that the strategic relationship will provide both parties with the expected benefits; and that market conditions will remain favorable for critical metals projects and alumina technologies. Many factors could cause the Company’s actual results to differ materially from those expressed or implied by the forward-looking statements contained in this news release. Such factors include, among other things: adverse market conditions; general economic, market or business risks; unanticipated costs; the failure of the Company to obtain any necessary regulatory approvals for the Transaction, including TSXV approval; the failure of either party to satisfy the remaining conditions to Closing; the failure by either or both parties to realize the expected benefits of the strategic relationship; changes in demand for critical minerals or alumina; and the risks and uncertainties described in the Company’s most recent Management’s Discussion & Analysis for the interim period ended June 30, 2026, which can be accessed at the Company’s profile on www.sedarplus.com. This list is not exhaustive of the factors that may affect any of the Company’s forward-looking statements. These and other factors should be considered carefully and accordingly, readers should not place undue reliance on forward-looking information. The “forward-looking statements” contained herein speak only as of the date of this news release and, unless required by applicable law, the Company undertakes no obligation to publicly update or revise such information, whether as a result of new information, future events or otherwise.